HIV trial testing doravirine plus raltegravir in adults
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have documented HIV-1 infection
- Have CD4 counts at least 200 (a blood test showing immune strength)
- Have had stable HIV treatment for at least 6 months using at least two HIV medicines
- Have HIV viral load suppressed (≤50) in the last year, with only limited minor “blips”
- Not have known resistance mutations to doravirine or raltegravir, based on your HIV test results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study tests switching your current HIV medicines to a once-daily pill combining doravirine, tenofovir, and lamivudine, specifically for people whose virus has a past M184V mutation but is now well controlled.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.